These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 20849734)

  • 1. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
    Takeda A; Cooper K; Bird A; Baxter L; Frampton GK; Gospodarevskaya E; Welch K; Bryant J
    Health Technol Assess; 2010 Sep; 14(42):1-209, iii-iv. PubMed ID: 20849734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
    Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT
    Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
    Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
    J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant growth hormone in children and adolescents with Turner syndrome.
    Cave CB; Bryant J; Milne R
    Cochrane Database Syst Rev; 2003; (3):CD003887. PubMed ID: 12917993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term growth, cost-effectiveness, and glycemic effects of growth hormone therapy on children born small for gestational age over 10 years: a retrospective cohort study.
    Al Khalifah RA; Alhakami A; AlRuthia Y; Al Sarraj HZ; Abulqasim J; Al-Rasheedi A; NurHussen A; Naji A
    J Pediatr Endocrinol Metab; 2022 Nov; 35(11):1357-1368. PubMed ID: 36203313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of somatropin for the treatment of short children born small for gestational age.
    Christensen T; Buckland A; Bentley A; Djurhuus C; Baker-Searle R
    Clin Ther; 2010 Jun; 32(6):1068-82. PubMed ID: 20637961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.
    Soliman AT; Elawwa A; Itani M; Jour C; De Sanctis V
    Acta Biomed; 2019 Sep; 90(8-S):43-51. PubMed ID: 31544806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone prescribing patterns in the UK, 2013-2016.
    Shepherd S; Saraff V; Shaw N; Banerjee I; Patel L
    Arch Dis Child; 2019 Jun; 104(6):583-587. PubMed ID: 30567827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of recombinant human growth hormone in children with different etiologies of dwarfism from a pharmacoeconomic point of view.
    Ma Y; Sheng J; Wang L; Zhang Y; Liu L
    Medicine (Baltimore); 2024 Jun; 103(25):e38350. PubMed ID: 38905369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden.
    Christensen T; Fidler C; Bentley A; Djurhuus C
    J Med Econ; 2010 Mar; 13(1):168-78. PubMed ID: 20136580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G; Baur F; Schweizer R; Ranke MB
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant growth hormone for children and adolescents with Turner syndrome.
    Baxter L; Bryant J; Cave CB; Milne R
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003887. PubMed ID: 17253498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort.
    Maghnie M; Ranke MB; Geffner ME; Vlachopapadopoulou E; Ibáñez L; Carlsson M; Cutfield W; Rooman R; Gomez R; Wajnrajch MP; Linglart A; Stawerska R; Clayton PE; Darendeliler F; Hokken-Koelega ACS; Horikawa R; Tanaka T; Dörr HG; Albertsson-Wikland K; Polak M; Grimberg A
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3287-3301. PubMed ID: 36102184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of growth hormone in children.
    Hindmarsh PC; Dattani MT
    Nat Clin Pract Endocrinol Metab; 2006 May; 2(5):260-8. PubMed ID: 16932297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation.
    Clegg AJ; Loveman E; Gospodarevskaya E; Harris P; Bird A; Bryant J; Scott DA; Davidson P; Little P; Coppin R
    Health Technol Assess; 2010 Jun; 14(28):1-192. PubMed ID: 20546687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.